Results 121 to 130 of about 17,845 (225)

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

, 2016
Objectives: To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation. Methods: Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day ...
Owen, A, Else, L, Boffito, M, Amara, A, Elliot, E, Khoo, S, Moyle, G, Back, D, Jackson, A   +8 more
core   +1 more source

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

The Lancet HIV
BACKGROUND The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance.
Graeme Moyle, L. Assoumou, N. De Castro, Frank A. Post, Adrià Curran, S. Rusconi, Stéphane De Wit, C. Stephan, F. Raffi, Margaret Johnson, Mar Masiá, Jaime F. Vera, B. Jones, R. Grove, C. Fletcher, Annie Duffy, Kellie Morris, A. Pozniak   +17 more
semanticscholar   +1 more source

Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon

AIDS Research and Therapy
Background HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment.
Christian Mangala, Rolf Moukanda-Ifoundou, Denis Maulot-Bangola, Alain Moutsinga, Christian Mombo-Maganga, Serge Christian Okolongo-Mayani, Brice Ongali, Guy Joseph Lemamy, Rachyda Massolou-Outata   +8 more
doaj   +1 more source

Perfil de resistencias y barrera genética de dolutegravir

, 2015
Dolutegravir tiene un perfil de resistencias significativamente distinto al de anteriores inhibidores de la integrasa. Es activo in vitro frente a VIH-1 (virus de la inmunodeficiencia humana-1) portador de cualquier mutación aislada de resistencia en ...
Llibre, Josep M., Clotet, Bonaventura
core   +1 more source

Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART

Open Forum Infectious Diseases
Dolutegravir resistance is emerging in routine clinical contexts in southern Africa, primarily in patients with prior treatment experience failing dolutegravir-based antiretroviral therapy (ART).
Richard A Murphy, Pradeep H Bedesi, Nirmala Perumal, B. Gosnell, T. Hatlen, J. Brijkumar   +5 more
semanticscholar   +1 more source

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.

, 2019
Birth outcome data with dolutegravir exposure during pregnancy, particularly in the first trimester, are needed. Data were prospectively collected from the Antiretroviral Pregnancy Registry and European Pregnancy and Paediatric HIV Cohort Collaboration ...
Vannappagari, Vani, Thorne, Claire, for APR and EPPICC   +2 more
core   +1 more source

Dolutegravir: A new option for HIV treatment

, 2014
The need for new strategies for treating HIV-1 infection has led to the development of a number of new drugs. The aim of this article is to review the latest results of clinical trials of dolutegravir, an integrase inhibitor whose efficacy, tolerability ...
Carbone, Alessia, CASTAGNA, ANTONELLA, LAZZARIN, ADRIANO   +2 more
core   +1 more source

Pharmacogenetics of Plasma Dolutegravir Exposure During 1-Month Rifapentine/Isoniazid Treatment of Latent Tuberculosis

In Advancing Clinical Therapeutics Globally protocol A5372, a pharmacokinetic study of dolutegravir with 1-month of daily rifapentine/isoniazid, twice-daily dolutegravir offset the induction effects of rifapentine on plasma dolutegravir trough ...
Gelmanova, Irina, Avihingsanon, Anchalee, Podany, Anthony T, Swindells, Susan, Savic, Rada, Dooley, Kelly E, Cramer, Yoninah, Arduino, Roberto C, Dawson, Rodney, Rosenkranz, Sue, Covington, Nia, Imperial, Marjorie Z, Haas, David W, Luetkemeyer, Anne F, Samaneka, Wadzanai   +14 more
core   +1 more source

Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania

AIDS Research and Therapy
Background The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment.
Revocatus T. Majula, Clement N. Mweya
doaj   +1 more source

¿La combinación dolutegravir y rifampicina en los pacientes no incluidos en los ensayos clínicos es también eficaz y segura en el binomio VIH-infección micobacteriana? Casos de la práctica clínica

Medicina Clínica Práctica
Resumen: Introducción: las infecciones micobacterianas (IM) y la infección por VIH (iVIH) siguen siendo un binomio frecuente. La rifampicina dificulta el uso de los antirretrovirales.
Sara Fontserè Recuenco, Rafael Luque-Márquez   +1 more
doaj   +1 more source